Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone versus cyproterone acetate for feminising hormone therapy in transgender adults
ACTRN12620000339954Phase 4Completed
- Sponsor
- Austin Health
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of spironolactone, cyproterone and estradiol in gender dysphoria (GD) (2 arms), sponsored by Austin Health. Primary endpoint: Breast growth. Started Aug 2020; status: completed.
02
Drugs
spironolactonecyproteroneestradiol
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on ACTRN12620000339954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000339954.